AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

AstraZeneca (AZN) announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab), for use in children. The regulatory body has now approved Fasenra as an add-on maintenance treatment for severe asthma in patients aged six to 11 years with an eosinophilic phenotype.Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA) in patients aged 12 and older.The latest approval for Fasenra was based on data from the open-label phase III TATE study, as ...